If the filing
person has previously filed a statement on Schedule 13G to report the acquisition which is subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
The information required on the remainder of this cover page
shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (the Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
1.
|
|
Name of
Reporting Person:
SVLSF IV, LLC
|
2.
|
|
Check the Appropriate Box if a Member
of Group (See Instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only:
|
4.
|
|
Source of Funds:
OO
|
5.
|
|
Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e): ☐
|
6.
|
|
Citizenship or Place of
Organization:
Delaware
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person With:
|
|
7.
|
|
Sole Voting Power:
0
|
|
8.
|
|
Shared Voting Power:
1,841,919 (1)
|
|
9.
|
|
Sole Dispositive Power:
0
|
|
10.
|
|
Shared Dispositive Power:
1,841,919 (1)
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person:
1,841,919 (1)
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares: ☐
|
13.
|
|
Percent of Class Represented By Amount
In Row (11):
7.2% (2)
|
14.
|
|
Type of Reporting Person:
OO
|
(1)
|
Voting and investment power of the securities is delegated to SVLSF IV, LLC, the general partner of SV Life Sciences Fund IV (GP), L.P., which is the general partner of each of SV Life Sciences Fund IV, L.P. and SV Life
Sciences Fund IV Strategic Partners, L.P.
|
(2)
|
Percentage calculated using a denominator of 25,478,820 shares of Common Stock of Issuer outstanding as of December 1, 2017.
|
2
|
|
|
|
|
|
|
1.
|
|
Name of
Reporting Person:
SV Life Sciences Fund IV (GP), L.P.
|
2.
|
|
Check the Appropriate Box if a Member
of Group (See Instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only:
|
4.
|
|
Source of Funds:
OO
|
5.
|
|
Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e): ☐
|
6.
|
|
Citizenship or Place of
Organization:
Delaware
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person With:
|
|
7.
|
|
Sole Voting Power:
0
|
|
8.
|
|
Shared Voting Power:
1,841,919 (1)
|
|
9.
|
|
Sole Dispositive Power:
0
|
|
10.
|
|
Shared Dispositive Power:
1,841,919 (1)
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person:
1,841,919 (1)
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares: ☐
|
13.
|
|
Percent of Class Represented By Amount
In Row (11):
7.2% (2)
|
14.
|
|
Type of Reporting Person:
PN
|
3
|
|
|
|
|
|
|
1.
|
|
Name of
Reporting Person:
SV Life Sciences Fund IV, L.P.
|
2.
|
|
Check the Appropriate Box if a Member
of Group (See Instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only:
|
4.
|
|
Source of Funds:
OO
|
5.
|
|
Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e): ☐
|
6.
|
|
Citizenship or Place of
Organization:
Delaware
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person With:
|
|
7.
|
|
Sole Voting Power:
0
|
|
8.
|
|
Shared Voting Power:
1,791,070 (1)
|
|
9.
|
|
Sole Dispositive Power:
0
|
|
10.
|
|
Shared Dispositive Power:
1,791,070 (1)
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person:
1,791,070 (1)
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares: ☐
|
13.
|
|
Percent of Class Represented By Amount
In Row (11):
7.0% (2)
|
14.
|
|
Type of Reporting Person:
PN
|
4
|
|
|
|
|
|
|
1.
|
|
Name of
reporting person:
SV Life Sciences Fund IV Strategic Partners, L.P.
|
2.
|
|
Check the appropriate box if a member
of group (see instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC use only:
|
4.
|
|
Source of funds:
OO
|
5.
|
|
Check if disclosure of legal
proceedings is required pursuant to
Items
2(d)
or
2(e):
☐
|
6.
|
|
Citizenship or place of
organization:
Delaware
|
Number of
shares
beneficially
owned by
each
reporting
person
with:
|
|
7.
|
|
Sole voting power:
0
|
|
8.
|
|
Shared voting power:
50,849 (1)
|
|
9.
|
|
Sole dispositive power:
0
|
|
10.
|
|
Shared dispositive power:
50,849 (1)
|
11.
|
|
Aggregate amount beneficially owned by each reporting person:
50,849 (1)
|
12.
|
|
Check if the aggregate amount in Row
(11) excludes certain shares: ☐
|
13.
|
|
Percent of class represented by amount
in Row (11):
0.2% (2)
|
14.
|
|
Type of reporting person:
PN
|
5
|
|
|
|
|
|
|
1.
|
|
Name of
Reporting Person:
ILSF III, LLC
|
2.
|
|
Check the Appropriate Box if a Member
of Group (See Instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only:
|
4.
|
|
Source of Funds:
OO
|
5.
|
|
Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e): ☐
|
6.
|
|
Citizenship or Place of
Organization:
Delaware
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person With:
|
|
7.
|
|
Sole Voting Power:
0
|
|
8.
|
|
Shared Voting Power:
1,114,537 (3)
|
|
9.
|
|
Sole Dispositive Power:
0
|
|
10.
|
|
Shared Dispositive Power:
1,114,537 (3)
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person:
1,114,537 (3)
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares: ☐
|
13.
|
|
Percent of Class Represented By Amount
In Row (11):
4.4% (2)
|
14.
|
|
Type of Reporting Person:
OO
|
(3)
|
Voting and investment power of the securities is delegated to ILSF III, LLC, the general partner of International Life Sciences Fund III (GP), L.P., which is the general partner of each of International Life Sciences
Fund III (LP1), L.P., International Life Sciences Fund III Co-Investment, L.P. and International Life Sciences Fund III Strategic Partners, L.P.
|
6
|
|
|
|
|
|
|
1.
|
|
Name of
Reporting Person:
International Life Sciences Fund III (GP), L.P.
|
2.
|
|
Check the Appropriate Box if a Member
of Group (See Instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only:
|
4.
|
|
Source of Funds:
OO
|
5.
|
|
Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e): ☐
|
6.
|
|
Citizenship or Place of
Organization:
Delaware
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person With:
|
|
7.
|
|
Sole Voting Power:
0
|
|
8.
|
|
Shared Voting Power:
1,114,537 (3)
|
|
9.
|
|
Sole Dispositive Power:
0
|
|
10.
|
|
Shared Dispositive Power:
1,114,537 (3)
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person:
1,114,537 (3)
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares: ☐
|
13.
|
|
Percent of Class Represented By Amount
In Row (11):
4.4% (2)
|
14.
|
|
Type of Reporting Person:
PN
|
7
|
|
|
|
|
|
|
1.
|
|
Name of
Reporting Person:
International Life Sciences Fund III (LP1), L.P.
|
2.
|
|
Check the Appropriate Box if a Member
of Group (See Instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC Use Only:
|
4.
|
|
Source of Funds:
OO
|
5.
|
|
Check if Disclosure of Legal
Proceedings is Required Pursuant to Items 2(d) or 2(e): ☐
|
6.
|
|
Citizenship or Place of
Organization:
Delaware
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person With:
|
|
7.
|
|
Sole Voting Power:
0
|
|
8.
|
|
Shared Voting Power:
1,091,166 (3)
|
|
9.
|
|
Sole Dispositive Power:
0
|
|
10.
|
|
Shared Dispositive Power:
1,091,166 (3)
|
11.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person:
1,091,166 (3)
|
12.
|
|
Check if the Aggregate Amount in Row
(11) Excludes Certain Shares: ☐
|
13.
|
|
Percent of Class Represented By Amount
In Row (11):
4.3% (2)
|
14.
|
|
Type of Reporting Person:
PN
|
8
|
|
|
|
|
|
|
1.
|
|
Name of
reporting person:
International Life Sciences Fund III Co-Investment,
L.P.
|
2.
|
|
Check the appropriate box if a member
of group (see instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC use only:
|
4.
|
|
Source of funds:
OO
|
5.
|
|
Check if disclosure of legal
proceedings is required pursuant to
Items
2(d)
or
2(e):
☐
|
6.
|
|
Citizenship or place of
organization:
Delaware
|
Number of
shares
beneficially
owned by
each
reporting
person
with:
|
|
7.
|
|
Sole voting power:
0
|
|
8.
|
|
Shared voting power:
12,947 (3)
|
|
9.
|
|
Sole dispositive power:
0
|
|
10.
|
|
Shared dispositive power:
12,947 (3)
|
11.
|
|
Aggregate amount beneficially owned by each reporting person:
12,947 (3)
|
12.
|
|
Check if the aggregate amount in Row
(11) excludes certain shares: ☐
|
13.
|
|
Percent of class represented by amount
in Row (11):
0.1%
|
14.
|
|
Type of reporting person:
PN
|
9
|
|
|
|
|
|
|
1.
|
|
Name of
reporting person:
International Life Sciences Fund III Strategic Partners,
L.P.
|
2.
|
|
Check the appropriate box if a member
of group (see instructions):
(a) ☐ (b) ☐
|
3.
|
|
SEC use only:
|
4.
|
|
Source of funds:
OO
|
5.
|
|
Check if disclosure of legal
proceedings is required pursuant to
Items
2(d)
or
2(e):
☐
|
6.
|
|
Citizenship or place of
organization:
Delaware
|
Number of
shares
beneficially
owned by
each
reporting
person
with:
|
|
7.
|
|
Sole voting power:
0
|
|
8.
|
|
Shared voting power:
10,424 (3)
|
|
9.
|
|
Sole dispositive power:
0
|
|
10.
|
|
Shared dispositive power:
10,424 (3)
|
11.
|
|
Aggregate amount beneficially owned by each reporting person:
10,424 (3)
|
12.
|
|
Check if the aggregate amount in Row
(11) excludes certain shares: ☐
|
13.
|
|
Percent of class represented by amount
in Row (11):
0.0% (2)
|
14.
|
|
Type of reporting person:
PN
|
10
This Amendment No. 2 to Schedule 13D (
Amendment No. 2
) amends the Schedule 13D
originally filed with the Securities and Exchange Commission (the
Commission
) on February 3, 2015 and amended by Amendment No. 1 filed with the Commission on January 31, 2017 (as amended, the
Original
Schedule
), to report the execution and delivery of the Voting Agreement described in Item 4 below. Except as specifically amended by this Amendment No. 2, each Item of the Original Schedule remains unchanged. All capitalized terms
contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule.
Item 1.
|
Security and Issuer
|
This Amendment No. 2 relates to the shares of common stock, par value $0.001
per share (the
Common Stock
), of Entellus Medical, Inc., a Delaware corporation (the
Issuer
). The Issuers principal executive office is located at 3600 Holly Lane North, Suite 40, Plymouth, Minnesota
55447.
Item 4.
|
Purpose of Transaction
|
Item 4 of the Original Schedule is hereby amended to add the following:
On December 7, 2017, the Issuer, entered into an Agreement and Plan of Merger (the
Merger Agreement
) with Stryker Corporation, a Michigan
corporation (
Stryker
), and Explorer Merger Sub Corp., a Delaware corporation and wholly owned subsidiary of Stryker (
Merger Sub
). The Merger Agreement provides that, upon the terms and subject to the
satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into the Issuer (the
Merger
), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Stryker. Pursuant to
the terms of the Merger Agreement, at the effective time of the Merger (the
Effective Time
) and as a result of the Merger, each share of common stock of the Issuer issued and outstanding immediately prior to the Effective Time
(other than shares held by the Issuer, Stryker, any subsidiary of Stryker or a stockholder who properly exercises and perfects appraisal of his, her or its shares under Delaware law) will be converted into the right to receive $24.00 in cash,
without interest (the
Merger Consideration
).
Concurrently with entering into the Merger Agreement, Reporting Persons SV Life Sciences
Fund IV, L.P., SV Life Sciences Fund IV Strategic Partners, L.P., International Life Sciences Fund III (LP1), L.P., International Life Sciences Fund III Co-Investment, L.P. and International Life Sciences Fund III Strategic Partners, L.P. (the
Signatories
) entered into a Voting Agreement with Stryker (the
Voting Agreement
) pursuant to which, among other things and subject to the terms and conditions therein, they agreed to vote their shares of the
Issuers common stock in favor of the adoption of the Merger Agreement and the transactions contemplated thereby, including the Merger, and against any alternative proposal. In addition, the Signatories waived appraisal rights and provided an
irrevocable proxy to Stryker to vote in favor of the Merger, including by voting for the adoption of the Merger Agreement. The Voting Agreement terminates upon the earliest to occur of (i) mutual consent by the relevant stockholder and Stryker; (ii)
the termination of the Merger Agreement in accordance with its terms; (iii) the Effective Time; (iv) the Issuers board of directors changes its recommendation that the Issuers stockholders adopt the Merger Agreement in accordance with
the terms of the Merger Agreement; and (v) in the event the Merger Agreement is amended without the prior written consent of a stockholder party to a Voting Agreement and such amendment, among other things, decreases the amount or changes the form
of Merger Consideration or otherwise is materially adverse to such stockholder relative to the other stockholders of the Issuer.
Based on the execution
of the Voting Agreement, the Reporting Persons and Stryker may be deemed to have formed a group within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended. Other than the Common Stock reported in Item 5 of
this report, the Reporting Persons expressly disclaim beneficial ownership of Issuer securities which may be beneficially owned by Stryker.
The foregoing
description of the Merger Agreements does not purport to be complete and is qualified in its entirety by reference to the
form 8-K
filed
by the Issuer on December 7, 2017 disclosing the foregoing. The foregoing description of the Voting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Voting Agreement, which is filed as
Exhibit 99.8 hereto and incorporated herein by reference.
11
Item 5.
|
Interest in Securities of the Issuer -
|
Item 5 of the Original Schedule is hereby amended and
restated in its entirety as set forth below.
(a) The aggregate percentage of Common Stock reported owned by Reporting Persons is based upon 25,478,820
shares of Common Stock outstanding, which is based on information provided by the Issuer as of December 1, 2017. The Common Stock is owned by the Reporting Persons as follows:
(i) Fund IV GP and SVLS General Partner may each be deemed to beneficially own, in the aggregate, 1,841,919 shares of Common Stock,
constituting approximately 7.2% of the Common Stock outstanding. As of the close of business on December 7, 2017, (a) Fund IV owned directly 1,791,070 shares of Common Stock, constituting approximately 7.0% of the Common Stock outstanding; and
(b) Fund IV Strategic owned directly 50,849 shares of Common Stock, constituting approximately 0.2% of the Common Stock outstanding.
Fund IV GP, the general partner of Fund IV and Fund IV Strategic, may be deemed to beneficially own the shares held by Fund IV and Fund IV
Strategic. Fund IV GP disclaims beneficial ownership of shares held by Fund IV and Fund IV Strategic except to the extent of any pecuniary interest therein.
SVLS General Partner, the general partner of Fund IV GP, may be deemed to beneficially own the shares held by Fund IV and Fund IV Strategic.
SVLS General Partner disclaims beneficial ownership of shares held by the Fund IV Entities except to the extent of any pecuniary interest therein.
The investment committee of SVLS General Partner, comprised of the members as set forth on
Schedule A
hereto, controls voting and
investment decisions over the Issuers shares held by Fund IV Entities by a majority vote. As such, no member of the investment committee of SVLS General Partner may be deemed to have any beneficial ownership of the Fund IV Shares.
(ii) Fund III GP and ILSF General Partner may each be deemed to beneficially own, in the aggregate, 1,114,537 shares of Common Stock,
constituting approximately 4.4% of the Common Stock outstanding. As of the close of business on December 7, 2017, (a) ILSF LP1 owned directly 1,091,166 shares of Common Stock, constituting approximately 4.3% of the Common Stock outstanding;
(b) ILSF Co-Invest owned directly 12,947 shares of Common Stock, constituting approximately 0.1% of the Common Stock outstanding; and (c) ILSF Strategic owned directly 10,424 shares of Common Stock, constituting approximately 0.0% of the
Common Stock outstanding.
Fund III GP, the general partner of ILSF LP1, ILSF Co-Invest and ILSF Strategic, may be deemed to beneficially
own the shares held by ILSF LP1, ILSF Co-Invest and ILSF Strategic. Fund III GP disclaims beneficial ownership of shares held by ILSF LP1, ILSF Co-Invest and ILSF Strategic except to the extent of any pecuniary interest therein.
ILSF General Partner, the general partner of Fund III GP, may be deemed to beneficially own the shares held by ILSF LP1, ILSF Co-Invest and
ILSF Strategic. ILSF General Partner disclaims beneficial ownership of shares held by the Fund III Entities except to the extent of any pecuniary interest therein.
The investment committee of ILSF General Partner, comprised of the members as set forth on
Schedule A
hereto controls voting and
investment decisions over the Issuers shares held by Fund III Entities by a majority vote. As such, no member of the investment committee of ILSF General Partner is deemed to have any beneficial ownership of the Fund III.
(b) Each of the Reporting Persons has shared voting and shared dispositive power with respect to all of the shares of Common Stock that the Reporting Person
beneficially owns. (i) Voting and investment power over the shares of Common Stock beneficially owned by Fund IV Entities has been delegated to Fund IV GP. Fund IV GP has delegated voting and investment decisions to SVLS General Partner, which,
in turn, has delegated such decisions to an investment committee comprised of the members as set forth on
Schedule A
hereto. (ii) Voting and investment power over the shares of Common Stock beneficially owned by Fund III Entities has
been delegated to Fund III GP. Fund III GP has delegated voting and investment decisions to ILSF General Partner, which, in turn, has delegated such decisions to an investment committee comprised of the members as set forth on
Schedule A
hereto. (iii) Each Reporting Person disclaims beneficial ownership of the securities except to the extent of any respective pecuniary interest therein, as described in Item 5(a).
12
(c) None of the persons on
Schedule A
hereto has effected any transactions in the Common Stock or other
equity security of the Issuer during the last 60 days.
(d) No person other than the Reporting Persons is known to have the right to receive, or the power
to direct the receipt of dividends from, or proceeds from the sale of, the beneficially owned Common Stock.
(e) Not applicable.
Item 6.
|
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
|
Item 6 of the Original Schedule is hereby amended to include the following paragraph at the end thereof:
The description of the Voting Agreement in Item 4 is incorporated herein by reference.
Item 7.
|
Material to be Filed as Exhibits.
|
Item 7 of the Original Schedule is hereby amended to add the
following exhibit:
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.8
|
|
Form of Voting Agreement, dated as of December 7, 2017, by and between Stryker Corporation and the applicable stockholder of Entellus
Medical, Inc.
|
13
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
|
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
SVLSF IV, LLC By: /s/ Denise Marks, Member
Signature of Reporting Person
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
ILSF III, LLC; By: /s/ Denise Marks, Member
Signature of Reporting Person
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
International Life Sciences Fund III (GP), L.P.; By: ILSF III, LLC, its General Partner; By: /s/ Denise
Marks, Member
Signature of Reporting Person
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
International Life Sciences Fund III (LP1), L.P.; By: International Life Sciences Fund III (GP), L.P., its General Partner; By: ILSF III,
LLC, its General Partner;
By: /s/ Denise Marks, Member
Signature of Reporting Person
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
International Life Sciences Fund III Co-Investment, L.P.; By: International Life Sciences Fund III (GP), L.P., its General Partner; By: ILSF
III, LLC, its General Partner;
By: /s/ Denise Marks, Member
Signature of Reporting Person
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
International Life Sciences Fund III Strategic Partners, L.P.; By: International Life Sciences Fund III (GP), L.P., its General Partner; By:
ILSF III, LLC, its General Partner;
By: /s/ Denise Marks, Member
Signature of Reporting Person
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
SV Life Sciences Fund IV (GP), L.P.; By: SVLSF IV LLC, its General Partner; By: /s/ Denise Marks, Member
Signature of Reporting Person
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
SV Life Sciences Fund IV Strategic Partners, L.P.; By: SV Life Sciences Fund IV (GP), L.P., its General
Partner; By: SVLSF IV, LLC, its General Partner; By: /s/ Denise Marks, Member
Signature of Reporting Person
|
|
|
|
|
Dated: December 11, 2017
|
|
|
|
|
|
SV Life Sciences Fund IV, L.P.; By: SV Life Sciences Fund IV (GP), L.P., its General Partner; By: SVLSF IV,
LLC, its General Partner; By: /s/ Denise Marks, Member
Signature of Reporting Person
|
Signature Page to Schedule 13D/A
Schedule A
Information regarding the members of the investment committees of SVLSF IV, LLC and ILSF III, LLC.
SVLSF IV, LLC
|
|
|
|
|
|
|
Name, Title
|
|
Address
|
|
Principal Occupation
|
|
Citizenship
|
|
|
|
|
James Garvey
|
|
c/o SV Life Sciences,
One Boston Place,
201 Washington
Street, Suite 3900, Boston,
MA 02108
|
|
Chairman Emeritus;
International life
sciences venture
capital investments
|
|
USA
|
|
|
|
|
Kate Bingham
|
|
c/o SV Life Sciences,
71 Kingsway,
London
WC2B 6ST
United Kingdom
|
|
Managing Partner;
International life
sciences venture
capital investments
|
|
United
Kingdom
|
|
|
|
|
Eugene D. Hill, III
|
|
c/o SV Life Sciences,
One Boston Place,
201 Washington
Street, Suite 3900, Boston,
MA 02108
|
|
Managing Partner;
International life
sciences venture
capital investments
|
|
USA
|
|
|
|
|
Michael Ross
|
|
c/o SV Life Sciences,
One Boston Place,
201 Washington
Street, Suite 3900, Boston,
MA 02108
|
|
Managing Partner;
International life
sciences venture
capital investments
|
|
USA
|
ILSF III, LLC
|
|
|
|
|
|
|
Name, Title
|
|
Address
|
|
Principal Occupation
|
|
Citizenship
|
James Garvey
|
|
c/o SV Life Sciences,
One Boston Place,
201 Washington
Street, Suite 3900, Boston,
MA 02108
|
|
Chairman Emeritus;
International life
sciences venture
capital investments
|
|
USA
|
|
|
|
|
Kate Bingham
|
|
c/o SV Life Sciences,
71 Kingsway,
London
WC2B 6ST
United Kingdom
|
|
Managing Partner;
International life
sciences venture
capital investments
|
|
United
Kingdom
|
|
|
|
|
Eugene D. Hill, III
|
|
c/o SV Life Sciences,
One Boston Place,
201 Washington
Street, Suite 3900, Boston,
MA 02108
|
|
Managing Partner;
International life
sciences venture
capital investments
|
|
USA
|
ILSF III, LLC
|
|
|
|
|
|
|
Name, Title
|
|
Address
|
|
Principal Occupation
|
|
Citizenship
|
Michael Ross
|
|
c/o SV Life Sciences,
One Boston Place,
201 Washington
Street, Suite 3900, Boston,
MA 02108
|
|
Managing Partner;
International life
sciences venture
capital investments
|
|
USA
|